A novel agent for preventing progression of muscle pathologies in muscular dystrophies

This project advances a novel therapeutic strategy to prevent fatty degeneration (FD) of skeletal muscle in Limb Girdle Muscular Dystrophy 2B (LGMD2B). LGMD2B, caused by dysferlin mutations, produces a characteristic and progressive replacement of muscle fibers with adipocytes and fibrotic tissue, particularly affecting shoulder and hip muscles and later limb muscles, frequently leaving patients wheelchair-bound by their thirties. There is no approved disease-modifying therapy for LGMD2B; common interventions are limited to physical therapy and supportive devices  and glucocorticoids effective in other muscular dystrophies are contraindicated because they worsen LGMD2B progression.

Against this unmet need, this team are developing Advertent Biotherapeutics' proprietary agent ADA011. ADA011 was identified for its potent inhibition of de novo adipogenesis in vitro. Translating these findings in vivo, the team demonstrated that ADA011 reduces muscle fatty degeneration and preserves muscle strength in the Bla/J mouse model of LGMD2B, establishing proof-of-concept efficacy in a relevant preclinical system. Beyond efficacy, the project reports favorable pharmacokinetic properties for ADA011 and an encouraging safety profile in mice, providing foundational data to support further preclinical development and potential clinical translation. The research emphasizes mechanistic targeting of adipogenic replacement processes that follow muscle fiber necrosis, aiming to halt or slow the replacement of functional muscle tissue with fat and fibrotic scar. By inhibiting the cellular and molecular steps that drive new adipocyte formation within degenerating muscle, ADA011 seeks to maintain muscle architecture and function, thereby preserving strength and delaying loss of mobility.

The work presented at the MDA Clinical & Scientific Conference 2026 integrates in vitro adipogenesis assays, histological evaluation of muscle FD, functional muscle strength testing in the Bla/J model, and pharmacokinetic and safety assessments collectively supporting ADA011 as a candidate therapeutic for LGMD2B. This research addresses a critical gap in treatment options for dysferlinopathy patients and lays groundwork for subsequent steps including dose optimization, extended safety testing and eventual clinical trial design. The combination of targeted anti-adipogenic activity with evidence of in vivo efficacy and tolerability positions ADA011 as a promising approach to prevent or reduce muscle fatty degeneration in LGMD2B, with the potential to alter disease trajectory and improve long-term outcomes for affected individuals.